IL6 and Miyoshi myopathy: Moreover, the tumor-promoting Th17/Th1 and Th22 cells and related cytokines (IL-17, IL-6, IL-1β etc.)were decreased in MM patients treated with IMiDs during induction chemotherapy compared to untreated patients, which was associated with a favorable clinical outcome (246).